We present long-term outcomes from a phase III randomized controlled trial that compared helical tomotherapy with three-dimensional conformal radiotherapy (3D-CRT) in the treatment of high-risk prostate cancer (PCa).
Newly diagnosed patients with high-risk PCa were randomly allocated to receive radical radiotherapy using 3D-CRT or helical tomotherapy. In both arms, patients received an initial dose of 46 Gy in 23 fractions to the prostate and pelvic lymph nodes followed by additional boost to the prostate of 32 Gy in 16 fractions. Radiotherapy was combined with 3 years of adjuvant androgen deprivation. The primary endpoint was late (>90 days since RT initiation) rectal toxicity.
Overall,123 patients were randomly assigned to either the 3D-CRT (n=60) or tomotherapy (n=63) arms. Median follow-up was 161 months. Overall, the proportion of patients with grade ≥2 late rectal toxicity was 8.3% (95% CI: 3.1 to 19.1; n=5) in the 3D-CRT arm and 11.1% (95% CI: 5.0 to 22.2; n=7) in the tomotherapy arm with no significant between-arm difference (p=0.83). There was no significant difference (p=0.17) in the proportion of patients with late grade ≥2 genitourinary toxicity:10.0% (95% CI: 4.1-21.2) in the 3D-CRT arm and 20.6% (95% CI: 11.9-33.0) in the tomotherapy arm. There was no significant difference in the hazard of biochemical progression or death between the two groups (HR for the tomotherapy arm: 0.72; 95% CI: 0.46-1.15, p=0.17).
In this phase III trial, the overall incidence of grade ≥2 rectal toxicity was low and was not significantly different between the two arms. There was non-significant evidence of improved biochemical progression-free survival in patients treated with tomotherapy. These findings should be interpreted considering the possibility of type II errors due to limited sample size and low event rates.
NCT00326638.
International journal of radiation oncology, biology, physics. 2024 Jul 13 [Epub ahead of print]
Soumyajit Roy, Robert MacRae, Scott Grimes, Julia Malone, Michael Lock, Prateek Mehra, Scott C Morgan, Shawn Malone
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA. Electronic address: ., Department of Radiology, Radiation Oncology, and Medical Physics, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada., The Ottawa Hospital Research Institute, Ottawa, ON, Canada., Department of Radiation Oncology, London Regional Health Sciences Centre, University of Western Ontario, London, ON, Canada., Department of Radiology, Radiation Oncology, and Medical Physics, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. Electronic address: .